A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Public ClinicalTrials.gov record NCT02150967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
Study identification
- NCT ID
- NCT02150967
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 143 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2014 (Actual)
- Primary completion
- Mar 1, 2021 (Actual)
- Completion
- Feb 7, 2022 (Actual)
- Last update posted
- Jul 3, 2023
2014 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| QED Investigative Site | Phoenix | Arizona | 85054 | — |
| QED Investigative Site | Los Angeles | California | 90033 | — |
| QED Investigative Site | Los Angeles | California | 90095 | — |
| QED Investigative Site | San Francisco | California | 94158 | — |
| QED Investigative Site | Boston | Massachusetts | 02114 | — |
| QED Investigative Site | Detroit | Michigan | 48201 | — |
| QED Investigative Site | New York | New York | 10016 | — |
| QED Investigative Site | New York | New York | 10029 | — |
| QED Investigative Site | New York | New York | 10065 | — |
| QED Investigative Site | Columbus | Ohio | 43221 | — |
| QED Investigative Site | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02150967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 3, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02150967 live on ClinicalTrials.gov.